Article Information
History
- November 12, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- J.H.A. Creemers1,2,†,
- M.J. van der Doelen3,4,†,
- S. van Wilpe1,3,†,
- R. Hermsen5,
- T. Duiveman-de Boer1,
- D.M. Somford6,
- M.J.R. Janssen7,
- J.P.M. Sedelaar4,
- N. Mehra1,3,
- J. Textor1,8 and
- H. Westdorp1,3,*
- 1Department of Tumor Immunology, Radboudumc, Nijmegen, The Netherlands
- 2Oncode Institute, Nijmegen, The Netherlands
- 3Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands
- 4Department of Urology, Radboudumc, Nijmegen, The Netherlands
- 5Department of Nuclear Medicine, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands
- 6Department of Urology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands
- 7Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands
- 8Data Science group, Institute for Computing and Information Sciences, Radboud University, Nijmegen, The Netherlands
- ↵*Corresponding author:
Harm Westdorp, MD, PhD, Departments of Tumor Immunology and Medical Oncology, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands, Tel: +31-24-361-0354, Fax: +31-24-361-5025, E-mail: Harm.Westdorp{at}radboudumc.nl
↵† These authors contributed equally to this article.
Posted November 12, 2020.
Immunophenotyping reveals longitudinal changes in circulating immune cells during radium-223 therapy in patients with metastatic castration-resistant prostate cancer
